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What is the Natural History of 

















Median Survival in Cirrhosis 
Compensated Cirrhosis  9 yrs 





Hepatopulmonary syndrome  10 mos 
Spontaneous bacterial peritonitis   9 mos 
Hepatorenal syndrome 
 Type 1   6 mos 
 Type 2   2 wks 
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The Term “Minority" 
■ In socioeconomics, typically 
refers to a socially ethnic group 
(understood in terms of 
language, nationality, religion 
and/or culture.  
 
■ Other minority groups include 
people with disabilities, 
"economic minorities" (working 




■ Refers to gaps in the 
quality of health and 
health care across 





■ There are an estimated 40 million Latinos 
living in the United States.  
 
■ By the year 2050, it is estimated that Latinos 
will comprise 25% of the U.S. population, 
which makes Latinos the largest and fastest 
growing minority group in the U.S. 
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Current Situation 
■ The prevalence of hepatitis C (HCV) among 
Latinos is estimated at 2.1%  
 
■ Which is significantly higher than the 
estimated prevalence of 1.8% in the general 




Alter MJ, et al.  N Engl J Med 1999;341:556-62  
Current Situation 
■ There are however many factors that could 
affect diagnosis, disease progression and 




■ Latinos with hepatitis C virus (HCV) infection 
have more rapid progression of fibrosis and 
decreased response to anti-HCV treatment.1  
■ The high rates of metabolic syndrome, insulin 
resistance, and hepatic steatosis, as well as 
genetic differences, may explain the severity 
of chronic hepatitis C (CHC) in this 
population.2 
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1. Verma S, et al.  Am J Gastroenterol 2006;101:1817-23. 
2. Wong R, et al. Am J Med 2008;121:525-31. 
Current Situation 
■ In addition, Latinos encounter substantial 
barriers to medical care. 
 
■ Including language, cultural differences, and 
socioeconomic factors such as lack of 
medical insurance.  
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Who We Are 
■ Largest academic community 
hospital in PA 
■ Largest Level 1 Trauma 
Center in PA 
■ Certified Stroke Center 
■ Employees – 9,656 
    Medical Staff – 1,100+ 
 Nurses – 2,334 
■ Magnet Hospital 
■ 154,792 ED visits / 
63,743 admissions 
■ 988 acute care beds 
■ 3 hospital campuses 
■ Revenues over  
 $1 Billion 
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Who We Are 
■ Our network maintains a strong 
academic presence with 15 free 
standing, fully accredited training 
programs.  
■ The not-for-profit network has a major 
affiliation with the University of South 
Florida as well as a long-standing 
affiliation with Penn State College of 
Medicine/Hershey Medical Center.  
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Who We Are 




■ Located 1 hour north of 
Philadelphia and 1.5 hours 
west of New York City.  
■ Third largest metropolitan 
region in PA 




■ Demonstrate the multiple factors influenced 
by race and ethnicity that affect response to 
peginterferon/ribavirin therapy for chronic 
hepatitis C.   
■ Describe how aspects of a multidisciplinary 
chronic care model, such as the patient-
centered medical home, can be applied to the 
management of hepatitis C to improve 
outcomes in a diverse population   
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Hepatitis C: A Curable Infection 
■ Pegylated interferon/ribavirin therapy offers a 
chance to eradicate hepatitis C 
– Genotype 1 – 40% 
– Genotype 2,3 – 75%-90% 
– Genotype 4 – 55% 
■ Sustained Virologic Response (SVR) 
– HCV RNA < LLD measured 24 weeks 
following completion of therapy 

















































































Agostino NM, Yozviak JL SGIM 2009 
Yet, The Cure Remains Elusive 
■ Many comorbidities influence response negatively 
– HIV, Obesity, Hepatic steatosis, Prediabetes/Diabetes 
– Mental Illness, Addiction 
■ Access to care remains problematic 
– Uninsured, Medicaid, Medicare 
– Minorities 
– Community providers may be disengaged 
■ We proposed that integration of a hepatitis C 
treatment program into an existing multidisciplinary, 
multicultural practice employing a chronic care model 
successful in other disease states can both increase 
access to care and improve treatment outcomes.  
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Hepatitis Care Center 
■ Merged services with LVHN AIDS Activities Office: A True Medical 
Home 
– Ryan White CARE Act (HIV primary care practice) 
– More than a decade of experience with viral hepatitis treatment 
(HBV and HCV) 
– Experts in adherence support 
■ Multidisciplinary staff 
– General Internists with Viral Hepatitis/HIV Focus of Practice 
– 50% bilingual (English and Spanish) 
– RN/case manager 
– LCSW mental health coordinator 
– Dietician 
– Research 
– Trained medical interpreters 
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Maximizing Outcomes With 
Current Therapies 
■ Maximizing number of patients completing therapy = increased SVR 
■ Focus on preparation for treatment 
– Repetitive education by multiple disciplines 
– Stabilize and optimize treatment of psychiatric disease/addiction 
– Achieve 10% weight loss if BMI elevated or evidence of insulin resistance; 
aggressively manage diabetes 
– Partner with primary care physicians (PCP) to optimize management of 
underlying medical conditions 
– Partner with PCP and psychiatrists, providing clear expectations for 
management of comorbidities on treatment 
– Build support system within practice and at home, prior 
to starting therapy 
■ Should translate into improved adherence, completion of therapy, and SVR 
Demographics 
Race/Ethnicity 
White 43% (33) 
Hispanic 41% (31) 
Black 11% (8) 
Asian 3% (2) 
Egyptian 3% (2) 
Sex  
Male 49% (37) 
Female 51% (39) 
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■ 61 patients have 
































Genotype 1 Genotype 2 Genotype 3
Genotype 4 Genotype 6
Completion of Therapy 
24 
N = 63















Total White Hispanic Black Other



















Total White Hispanic Black Other


























Total White Hispanic Black
Total  Genotype 1 Genotype 2 Genotype 3
Discussion 
■ Supporting patients through peginterferon/ribavirin 
therapy involves a multifaceted approach 
■ The use of a multidisciplinary treatment model in a 
multicultural practice resulted in high rates of 
completion for patients of most races/ethnicities 
■ Our approach of coordinating management of 
medical, psychiatric, and social conditions in a 
complex and diverse patient population resulted in 
rates of SVR comparable to those of clinical trials 
with highly selected participant populations 
– Genetic predispositions (e.g. IL28B) continue to lead to 
disparate rates of SVR with current therapies 
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SVR Comparisons: 
Focus on White Patients 
28 
1. Freilich B, et al.  57th AASLD 2006. 



















Overall Genotype 1 Genotype 2/3
LVHN Win-R LATINO
SVR Comparisons: 
Focus on Hispanic Patients 
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1. Freilich B, et al.  57th AASLD 2006. 



















Overall Genotype 1 Genotype 2/3
LVHN Win-R LATINO
Discussion (cont.) 
■ By focusing efforts on stabilization of 
medical/psychiatric comorbidities and preparation of 
patients for peginterferon/ribavirin therapy, treatment 
of HCV can be provided to a broader population.  
■ This model of care can be replicated, particularly in 
practices transitioning to become patient-centered 
medical homes, where medical, case management, 
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Hepatitis Care Center 
610-969-4239 
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